South Staffordshire Joint FormularyCannock Chase Clinical Commissioning Group East Staffordshire Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group
NOT for new patients - more toxic in overdose. (MHRA December 2007).
NHS England has identified this product as an item that should not be routinely prescribed in primary care. Where ongoing primary care prescribing is agreed in exceptional circumstances, there should be a co-operative relationship within a multidisciplinary team (July 2017).
Cost effective choice in patients where QT interval prolongation is not an issue (see MHRA advice below for detail) Maximum daily dose 40 mg for adults; 20 mg for patients older than 65 years; and 20 mg for those with hepatic impairment.
Use the orodispersible tablets where there are swallowing difficulties or patient is on a 10mg dose as the tablet can be divided into equal halves to get the correct dose. This is much more cost effective then the oral solution